MedPath

Phase II study of hepatic arterial infusion of cisplatin for unresectable intrahepatic cholangiocarcinoma

Phase 2
Conditions
intrahepatic cholangiocarcinoma
Registration Number
JPRN-UMIN000000809
Lead Sponsor
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
35
Inclusion Criteria

Not provided

Exclusion Criteria

1) presence of uncontrollable ascites or pleural effusion 2) cerebral or bone metastasis 3) uncontrollable cardiovascular disease or prior myocardial infarction 4) active infection other than HBV or HCV 5) other malignancy 6) severe psychiatric disorder 7) severe drug allergy 8) pregnant or nursing

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath